Skip to main content

Table 2 Baseline demographics and clinical characteristics of patients with Crohn’s disease

From: Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

Index Treatment group VDZ Anti-TNFα VDZ Anti-TNFα VDZ Anti-TNFα
Treatment history [Total N] Biologic-naïve [N = 10] Biologic-naïve [N = 65] Prior anti-TNFα [N = 59] Prior anti-TNFα [N= 40] Total [N = 69] Total [N = 105]
Female, % 60 52 68 60 67 55
Age at index, years, median (range) 39.0 (21–70) 38.0 (18–72) 42.0 (20–73) 40.5 (21–58) 41.0 (20–73) 39.0 (18–72)
CD duration, years, median (range) [n with available data]a 8.2 (0–30) [10] 3.7 (0–50) [65] 10.1 (1–35) [58] 7.2 (0–33) [40] 9.8 (0–35) [68] 5.6 (0–50) [105]
CD location, [n] [9] [57] [57] [34] [66] [91]
 Ileal, % 22 18 26 24 26 20
 Colonic, % 33 28 23 15 24 23
 Ileocolonic, % 44 54 51 62 50 57
Disease behavior, [n] [9] [60] [52] [34] [61] [94]
 Non-stricturing, non-penetrating, % 44 65 67 38 64 55
 Stricturing, % 44 22 21 41 25 29
 Penetrating, % 11 13 12 21 11 16
Prior IBD-related surgery, % 20 35 42 45 39 39
HBI score, [n] [3] [10] [10] [13] [13] [23]
 0–4 (remission), % 33 40 30 46 31 43
 5–7 (mild activity), % 33 60 30 15 31 35
 8–16 (moderate activity), % 33 0 40 38 38 22
  ≥ 17 (severe activity), % 0 0 0 0 0 0
Abdominal pain score, [n] [5] [46] [36] [22] [41] [68]
 0 (none), % 20 39 25 41 24 40
 1 (mild), % 0 20 19 18 17 19
 2 (moderate), % 80 37 47 27 51 34
 3 (severe), % 0 4 8 14 7 7
Liquid/soft stools per day, mean (SD) [n] 3.7 (2.5) [3] 3.6 (3.8) [35] 5.2 (4.9) [26] 3.8 (4.7) [21] 5.0 (4.7) [29] 3.7 (4.1) [56]
Endoscopic score, [n] [6] [39] [30] [26] [36] [65]
 0 (normal or inactive disease), % 17 10 27 27 25 17
 1 (mild disease), % 17 21 20 19 19 20
 2 (moderate disease), % 33 46 20 23 22 37
 3 (severe disease), % 33 23 33 31 33 26
Corticosteroids in past 2 years, % 60 69 58 53 58 63
Aminosalicylates in past 2 years, % 20 37 31 45 29 40
Immunomodulators in past 2 years, % 20 57 29 48 28 53
Duration of previous anti-TNFα treatment, months, mean (SD), [n] – – 31.6 (24.3) [52] 22.3 (20.7) [39] 31.6 (24.3) [52] 22.3 (20.7) [39]
Duration from prior anti-TNFα discontinuation to index date, months, median (range), [n] – – 1.1 (0–103) [57] 2.1 (0–57) [39] 1.1 (0–103) [57] 2.1 (0–57) [39]
Index treatment, anti-TNFα type
 Infliximab originator, % – 42 – 45 – 43
 Infliximab biosimilar, % – 18 – 20 – 19
 Adalimumab, % – 40 – 35 – 38
Concomitant therapy at index
 Corticosteroids, % 20 25 29 28 28 26
 Immunomodulators, % 10 19 8 18 9 18
 Aminosalicylates, % 0 14 15 20 13 16
  1. Anti-TNFα Anti-tumor necrosis factor alpha, CD Crohn’s disease, HBI Harvey Bradshaw Index, IBD Inflammatory bowel disease, SD Standard deviation, VDZ Vedolizumab
  2. aUnless otherwise indicated, data from the full population were available for analysis
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us